Bipolar Disorder Trial, Recruiting NCT07031817 Sponsor: University Hospital, Montpellier Condition: Bipolar Disorder
Back to Bipolar Disorder

Bipolar Disorder Trial, Recruiting

NCT07031817
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You identify as a cis man, cis woman, trans man, trans woman, or non-binary person
  • You are between 18 and 65 years old
  • You have been diagnosed with moderate to severe major depressive disorder (according to standard diagnostic guidelines) and are considered suitable for antidepressant treatment

Who may not be able to join:

  • People who are under legal guardianship, trusteeship, or court protection
  • People who have been diagnosed with schizophrenia
  • People who have taken certain psychiatric medications in the 5 days before joining the trial (or 21 days for specific medications like fluoxetine or aripiprazole), except for certain anti-anxiety medications used as directed
  • People who have an unstable or serious physical health condition, as judged by the trial doctor
  • People who are pregnant or breastfeeding
  • People with a known autoimmune disease (such as Crohn's disease or thyroid inflammation) or any condition that could affect certain blood test results (confirm with trial site)
  • People who are unable to give informed consent to take part
  • People not covered by a social security (health insurance) scheme
  • People already taking part in another interventional clinical trial
  • People who have been vaccinated less than 30 days before joining
  • People who have significant difficulties reading, understanding, or speaking French
  • People who develop a diagnosis of schizophrenia or a changed diagnosis during the trial may be withdrawn
  • People whose situation becomes incompatible with continuing the study, as judged by the trial doctor

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33 0467337913

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
30 September 2025
Est. completion
1 October 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Sensitivity and specificity of the composite medical device, using the full clinical evaluation as a reference

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov